hotspot -WSS

hotspot

author：fashion 2025-09-29 19:59:28 - browse：8221

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Clinical trials must include more disabled people

WSS

Evacuations in place as 3 wildfires burn in eastern Washington state

What is STAT's opinion section for?

FDA approves first treatment for ultra

Study suggests Covid rebound is far more common with Paxlovid than without

Eye stem cell transplant could help restore vision in injured people

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

hotspot

hotspot

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

New definition of a human embryo proposed amid rapid advances

Alkermes shareholders re

Ohio still needs to do more to protect the right to abortion

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

White House drug czar issues call for 'recovery

Cancer drug shortages should be causing more outrage

Carbon Health diabetes program, a test of data

Virginia high school admissions case could be legal follow

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

knowledge

Today's health inequities arise from racist U.S. history, say experts

After decades in use, heart stents finally beat placebo

FDA approves first treatment for ultra

How state and local governments are sidelining science

ProMED sees offers of support, but its future remains unclear

Experimental asthma app from Apple and Anthem shows promise

focus

explore

leisure time

knowledge